By Maureen Testoni March 11, 2021– In this pandemic-focused world we all find ourselves in, it seems only fitting that one of my highlights of this past month was getting the chance to meet Fauci. No, I’m not talking about the esteemed Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has become a household name over the past … [Read more...]
Drug Giant’s Revenues Soar While 340B Cuts Sting
February 10, 2021– While hospitals across the country have been struggling to stay afloat and serve the health needs of a nation during a historic pandemic, one of the largest drug companies in the U.S. has been boosting its already huge profits by denying safety-net providers the drug discounts that the 340B drug pricing program requires. Two new reports show that as drug … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
Government Opinion Paves the Way for Reversal of Drug Company Refusals to Provide 340B Discounts
Jan. 8, 2021– While many of us were preparing for an untraditional New Year’s Eve celebration, the federal government made a vitally important announcement about 340B. The administration unequivocally stated that drug companies denying 340B discounts to hospitals, health centers, and clinics that partner with community pharmacies are in violation of federal law. In an … [Read more...]
340B in 2020: A Year of Hope Amid Heartbreak
By Maureen Testoni December 22, 2020– We are coming to the end of a year like no other in our memories. A worldwide pandemic has caused the deaths of more than 300,000 of our fellow Americans. An economic recession has forced businesses to close and millions of hard-working people to lose their jobs and their income – and for many their health insurance. An election … [Read more...]
Drug Industry Report on 340B Attempts a Diversion from Unlawful Manufacturer Actions
October 14, 2020— A new report from the drug industry consultant Berkeley Research Group (BRG) takes aim at community-based pharmacies in the 340B drug pricing program. The report implies, without evidence, that for-profit pharmacy chains are making excessive profits on these arrangements. It ignores the fact that these partnerships provide critical funding for safety-net and … [Read more...]
JAMA Study Shows 340B Can Help Restrain Drug Price Hikes
September 22, 2020— A recent Wall Street Journal opinion piece by a pharmaceutical industry consultant resurfaces claims that statutory discounts for safety-net hospitals, health centers, and clinics are forcing drug companies to hike their prices. Drug manufacturers are using this false notion as a pretext for urging program cutbacks in the guise of “reforms” and for refusing … [Read more...]